CTIS2024-511266-36-00进行中（未招募）1 期
PRiME2_21_1
niversitaetsklinikum Tuebingen AöR0 个研究点目标入组 72 人开始时间: 2024年3月11日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Phase I, open-label, randomized, two period, cross-over study in healthy subjects to assess the bioavailability of different formulations of deucrictibant administered as single dose under fasting condition.Hereditary angioedema (HAE)MedDRA version: 23.1Level: PTClassification code: 10019860Term: Hereditary angioedema Class: 100000004850CTIS2024-511196-15-00Pharvaris Netherlands B.V.14
进行中（未招募）
1 期
Double-blind, randomized, placebo-controlled, pilot study to evaluate the safety, tolerability and efficacy of two doses of a conditioned medium from a co-culture of M2-macrophages and mesenchymal cells (PRS CK STORM) in the prevention of COVID-19-associated cytokine stormSARS-CoV-2 infectionMedDRA version: 23.0Level: LLTClassification code: 10084272Term: SARS-CoV-2 infection Class: 10021881CTIS2023-507700-32-00Peaches Biotech S.L.50
进行中（未招募）
1 期
A Phase I, open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of a 40 mg deucrictibant tablet administered once daily on the pharmacokinetics of the P-gp substrate digoxin and the BCRP substrate rosuvastatin, administered as a drug cocktailHereditary angioedemaCTIS2024-514713-35-0014
进行中（未招募）
1 期
A Phase 1, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent or metastatic adenoid cystic carcinoma.Adenoid cystic carcinoma (ACC)MedDRA version: 21.0Level: PTClassification code: 10053231Term: Adenoid cystic carcinoma Class: 100000004864CTIS2023-508476-11-00Remix Therapeutics Inc.80
招募中
1 期
Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM534 Administered Intravenously to Patients with Advanced Solid TumorsAdvanced Solid TumorsCTIS2024-513056-15-00Pharma Mar S.A.30